INTRODUCTION
The novel 2009 influenza A (H1N1) virus (A/H1N1/2009), which emerged in April 2009 in Mexico, rapidly spread worldwide leading to the declaration of a pandemic by the World Health Organization shortly after (Fraser et al., 2009; Zarocostas, 2009) . Although human disease caused by A/H1N1/2009 has so far appeared mostly to be relatively mild in Germany, a significant level of morbidity and hospitalization and several cases of severe illness and death have been observed (Chowell et al., 2009; Jamieson et al., 2009; Perez-Padilla et al., 2009; Vaillant et al., 2009) .
Rapid diagnosis of influenza is necessary to initiate antiviral therapy and infection control measures to reduce the spread of infection in healthcare settings, and leads to clinical and financial benefits (Barenfanger et al., 2000; Low, 2008) . For rapid diagnosis of seasonal influenza A/B, several rapid antigen tests, also referred to as point-of-care (POC) tests, are available. POC immunoassays detect viral antigen and can generate a result within 15 min or less (Storch, 2003) . In contrast to traditional laboratory assays, such as virus isolation from cell cultures or real-time PCR, POC tests are widely used in a routine clinical setting (D'Heilly et al., 2008; Noyola & Demmler, 2000) . Another rapid detection method for seasonal influenza is direct fluorescent antibody (DFA) staining of respiratory epithelial cells, which can generate results within 1-2 h (Habib-Bein et al., 2003; Smit et al., 2007) but requires specialized and experienced staff.
In contrast to seasonal influenza, the diagnosis of novel A/H1N1/2009 is currently based on RT-PCR only, a sensitive but time-consuming and costly method, which is not suitable for providing rapid diagnosis. To improve the clinical management of patients suspected to have A/H1N1/2009 infection, suitable rapid detection methods (POC tests or DFA staining) for A/H1N1/2009 would be useful. Several studies have investigated the diagnostic performance of these methods in different populations, with highly differing results and recommendations (Drexler et al., 2009; Faix et al., 2009; Ginocchio et al., 2009; Pollock et al., 2009; Vasoo et al., 2009 [comprising outpatients (n5402) and healthcare workers (n571) with mostly mild symptoms, and also inpatients (n553)] were analysed. Case definitions for novel influenza were used according to the recommendations of the National Reference Centre (Robert Koch Institute, Germany). Specimen types included nasopharyngeal swabs consisting of cotton swabs transported in 1-2 ml sterile saline, pharyngeal washes for which approximately 5-10 ml sterile saline was used, and bronchoalveolar lavage samples.
'Respiratory pools' were built by pooling 0.5-1.0 ml from each specimen into a fresh vial under sterile conditions if two or more specimens were available from the same patient (e.g. two swabs and one pharyngeal wash). This was carried out after excluding loss of sensitivity from the pool versus single sample testing (data not shown) in order to achieve an optimal detection rate and to reduce cost and hands-on time. A total of 526 samples (480 respiratory pools, 37 pharyngeal washes, seven nasopharyngeal swabs and two bronchoalveolar lavage samples) were analysed.
Statistical analysis. Statistical analysis was performed using SPSS version 16.0. P values of ,0.05 were considered significant. Pearson's x 2 test and a Mann-Whitney U test were applied to determine the statistical significance of differences between groups. For comparison of the analytical properties of the POC test, DFA staining and virus isolation, specimens positive for A/H1N1/2009 in the RT-PCR were considered to be true-positives. Sensitivity, specificity and positive (PPV) and negative (NPV) predictive values were calculated using standard formulae.
RNA extraction. Total viral RNA was extracted from a 140 ml aliquot of the respiratory specimen using a QIAamp Viral RNA kit in a QIAcube (Qiagen) according to the manufacturer's instructions, eluted in a volume of 50 ml and stored at 280 uC if not tested immediately. To ensure efficient nucleic acid extraction, as well as to exclude PCR inhibition, specimens were spiked with mengovirus, and for each sample an additional mengovirus RT-PCR was performed as published previously (Costafreda et al., 2006) .
RT-PCR for detection of respiratory viruses other than
A/H1N1/2009. A commercially available real-time RT-PCR kit (RealAccurate Respiratory RT-PCR kit; Pathofinder) was used as described previously (Gottlieb et al., 2009) to detect the following respiratory viruses: adenovirus, coronavirus types OC43 and 229E, influenza virus types A and B, human metapneumovirus (HMPV), parainfluenza virus (PIV) types 1-4, respiratory syncytial virus (RSV) types A and B, and rhino-/enterovirus. POC test. The QuickVue Influenza A+B POC test (Quidel), a lateral-flow immunoassay, was performed for 172/526 patients according to the manufacturer's instructions. Briefly, the dropper provided was used to transfer the recommended amount of liquid specimen into the extraction tube. In the case of swabs, the extraction reagent provided was added. Finally, the test strip was placed in the tube and the result was read after 10 min.
DFA staining. For DFA staining, specimens were centrifuged for 10 min at 500 g and the cell pellet was resuspended in a small amount of PBS. Ten microlitres of the resuspended pellet was transferred to a slide well, air dried and fixed in acetone at 220 uC for 10 min, followed by staining with mouse FITC-labelled influenza A virus monoclonal antibody (LIGHT DIAGNOSTICS; Millipore). A positive result was indicated by the presence of at least one cell showing specific fluorescence using a fluorescence microscope (Zeiss Axioskop 40). Specimens with an inadequate number of respiratory cells were considered invalid for DFA. Results for DFA staining were available for 172/526 patients.
Virus isolation. Virus isolation was performed for all 526 patients by application of 1-2 ml specimen onto MDCK cells, which were monitored at least twice weekly for up to 14 days for the emergence of a cytopathic effect.
RESULTS AND DISCUSSION

Patient demographics
Respiratory specimens from 526 patients were investigated. The median age of the patients was 24 years (range 0-84) and 47.5 % (250/526) were male.
Results of the A/H1N1/2009 real-time RT-PCR
In total, 48/526 patients (9.1 %) had a positive result in the A/H1N1/2009 RT-PCR, with a median C t value of 28.6 (range 16.5-36.5). Patients with a positive PCR result had a significantly lower age than patients with a negative PCR result [P50.015; median age 19 years (range 2-51) vs 25 years (range 0-84)]. The positive rate was higher in male (10.8 %; n527/250) compared with female (7.6 %; n5 21/276) patients. These data correlated well with the epidemiological situation in Germany during the study period (Gilsdorf & Poggensee, 2009 ).
Other respiratory viruses detected by the RealAccurate Respiratory RT-PCR
Almost one-third of the A/H1N1/2009 RT-PCR-negative samples (137/478; 28.7 %) were tested additionally using the RealAccurate Respiratory RT-PCR. In total, 42.3 % (58/137) of these specimens were positive, and 55 were positive for one of the following viruses: rhino-/enterovirus (28/137), adenovirus (11/137), PIV (7/137), coronavirus (4/137), HMPV (2/137), RSV (1/137) and influenza A/B virus (2/137). In 3/137 specimens, more than one virus could be detected. Only 2/137 specimens were positive for seasonal influenza A/B virus (which was also confirmed by an in-house PCR for seasonal influenza virus), indicating that, as expected, the prevalence of seasonal influenza strains, as well as other 'seasonal' viruses such as HMPV and RSV, was very low during the study period from May to September 2009. The high rate of entero-/rhinovirus detection is typical for the summer months (Weigl et al., 2007) . These data indicated that additional diagnostic testing for other respiratory viruses is required for negative A/H1N1/2009 tests during a pandemic. In addition to the rapid detection methods, we analysed the diagnostic performance of influenza virus isolation from cell culture for all 526 samples, finding a sensitivity of 45.7 %, specificity of 99.8 %, and a PPV of 95.5 % and NPV of 94.8 %. However, the median time required for virus isolation was 7.5 (range 3-10) days, indicating that virus isolation is only appropriate as a long-term method.
Our data suggested that the present version of the Quidel QuickVue POC test is not suitable for excluding A/H1N1/ 2009 infection due to its low sensitivity. Reduced POC test sensitivity due to inappropriate sample collection was unlikely, as the number of invalid DFA tests (e.g. due to an inadequate number of respiratory cells in the sample) was very low during the study. Similarly, low sensitivities have been reported for other POC tests (21.2 %) and DFA staining (47.2 %) (Ginocchio et al., 2009) . Another German study found an even lower sensitivity (11.1 %) for the BinaxNOW POC test (Drexler et al., 2009) . In contrast to this, other studies found slightly higher sensitivities of the Quidel POC test for A/H1N1/2009 detection, ranging from 40 to 61 % (Vasoo et al., 2009) or 35 to 67 % (Faix et al., 2009) . One group even reported a sensitivity of 93 % for DFA staining, recommending the use 
Conclusions
Although our data indicated that DFA staining is superior to POC testing for rapid detection of A/H1N1/2009, both methods were clearly less sensitive than the A/H1N1/2009 RT-PCR. Consequently, the negative results from these rapid detection methods cannot exclude novel influenza A/H1N1/2009 confidently and thus results should be verified by further PCR testing. Additionally, the data concerning the prevalence of other respiratory viruses indicated that these viruses should also be kept in mind during a pandemic.
The development of new or adaptation of existing assays for the rapid and sensitive detection of the novel A/H1N1/ 2009 will be necessary in order to improve the diagnosis and treatment of A/H1N1/2009-related influenza. Until these assays are established, DFA staining can be useful for 
